Dragoi, Andrei-Lucian M.
Biology / Medicine
October 28, 2020
Duchenne muscular dystroph, pharmacological therapy
BACKGROUND: Duchenne muscular dystrophy (DMD) is severe X-linked recessive congenital muscular dystrophy and the most common type of muscular dystrophy. Long-term corticosteroid therapy (LTCT) (started from the age of 4 years) is the most accessible and used pharmacological therapy of DMD in Romania. Several studies showed that "ASEA® redox supplement" (ARS) (which was approved as a dietary supplement in UE) is a very potent selective NRF2 activator, thus a very potent (indirect) antioxidant, with no toxicity up to high doses (in contrast with LTCT). PURPOSE: This research aims at discovering dietary supplements which may show comparable or even stronger beneficial effects (with less or none adverse effects) than LTCT in children with DMD whose parents refuse LTCT. METHODS: Three boy-patients with DMD (of ~4, ~5 and ~3 years of age) (whose parents refused LTCT) were treated with relatively high